Elevara Medicines Raises $70M Series A to Advance RA and Inflammatory Disease Program

Deal Summary

Elevara Medicines, a London-based clinical-stage biotech focused on rheumatoid arthritis and chronic inflammatory diseases, closed a $70M Series A financing co-led by Forbion and Sofinnova Partners with participation from Monograph Capital. The company will use the proceeds to fund its upcoming Phase 2 clinical trial.